<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00049309</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00008602</org_study_id>
    <secondary_id>DUMC-1385-02-7R3ER</secondary_id>
    <secondary_id>NCI-P02-0235</secondary_id>
    <secondary_id>CCUM-0202</secondary_id>
    <secondary_id>UMCC-0202</secondary_id>
    <secondary_id>CDR0000258042</secondary_id>
    <nct_id>NCT00049309</nct_id>
  </id_info>
  <brief_title>Low-Fat Diet and/or Flaxseed in Preventing Prostate Cancer</brief_title>
  <official_title>Prostate Cancer: Impact Of Fat And Flaxseed - Modified Diets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: A diet that is low in fat and/or high in flaxseed may slow or prevent disease&#xD;
      progression of prostate cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of a diet that is low in fat&#xD;
      and/or high in flaxseed in slowing or preventing disease progression in patients who have&#xD;
      newly diagnosed prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare tumor proliferation in patients with newly diagnosed prostate cancer eating fat-&#xD;
           and/or flaxseed-modified diets.&#xD;
&#xD;
        -  Compare differences in histopathological markers associated with prostate cancer (rates&#xD;
           of apoptosis, extent of high-grade prostatic intraepithelial neoplasia) among patients&#xD;
           in these diet groups.&#xD;
&#xD;
        -  Compare changes in serum prostate specific antigen among patients in these diet groups.&#xD;
&#xD;
        -  Compare changes in hormone-related factors (total serum testosterone and free androgen&#xD;
           index, insulin-like growth factor [IGF], and IGF-binding protein-3) among patients in&#xD;
           these diet groups.&#xD;
&#xD;
        -  Compare the effects of diet on nutritional biomarkers (levels of lignans in the urine&#xD;
           and ejaculate, fatty acid profiles of erythrocytes and prostatic tissue) in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine associations between dietary modification and changes in dietary biomarkers,&#xD;
           hormonal intermediates, and study endpoints in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to Gleason score (less&#xD;
      than 7 vs at least 7) and race (black vs non-black). Patients are randomized to 1 of 4 diet&#xD;
      groups.&#xD;
&#xD;
        -  Arm I (Flaxseed-supplemented diet): Patients are instructed to incorporate ground&#xD;
           flaxseed into their daily diets.&#xD;
&#xD;
        -  Arm II (Low-fat diet): Patients are instructed on ways to achieve a diet with no greater&#xD;
           than 20% of total energy from dietary fat.&#xD;
&#xD;
        -  Arm III (Flaxseed-supplemented, low-fat diet): Patients are instructed as in arm I and&#xD;
           arm II.&#xD;
&#xD;
        -  Arm IV (Control diet): Patients are contacted weekly, but do not receive dietary&#xD;
           counseling until after surgery.&#xD;
&#xD;
      All patients ingest the diets for at least 3 weeks and complete diet diaries until surgery.&#xD;
      After surgery, all patients receive dietary counseling.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 160 patients (40 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostatic Carcinoma Proliferation Rate by MIB-1 assay at time of prostatectomy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostatic Carcinoma Apoptotic Index by TUNEL assay at time of prostatectomy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific antigen by Hybritech assay at baseline and follow-up</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total testosterone, sex hormone binding globulin, insulin-like growth factor (IGF), and IGF-binding protein-3, total cholesterol, and low-density lipoprotein cholesterol by ELISA assays at baseline and follow-up</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flaxseed diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 gram flaxseed dietary modification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low fat diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low fat dietary modification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low fat + Flaxseed diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low fat and 30 gram flaxseed dietary modification</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dietary intervention</intervention_name>
    <arm_group_label>Low fat + Flaxseed diet</arm_group_label>
    <arm_group_label>Low fat diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>flaxseed</intervention_name>
    <arm_group_label>Flaxseed diet</arm_group_label>
    <arm_group_label>Low fat + Flaxseed diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed prostate cancer&#xD;
&#xD;
          -  At least 3 weeks until planned prostatectomy (24 days between day 1 visit and surgery)&#xD;
&#xD;
          -  Current diet that provides more than 30% of calories from fat&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Mentally competent&#xD;
&#xD;
          -  Able to speak and write English&#xD;
&#xD;
          -  Must have telephone access&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 2 weeks since prior prostate biopsy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 7 days since prior antibiotics&#xD;
&#xD;
          -  No prior therapy for prostate cancer&#xD;
&#xD;
          -  No concurrent dietary supplements initiated within the past 3 months or anticipated to&#xD;
             begin during study except standard multivitamin/mineral preparations (e.g., One-A-Day,&#xD;
             Theragran, or Centrum) that do not supply &gt; 100% of the recommended daily allowance of&#xD;
             any vitamin or mineral&#xD;
&#xD;
          -  No other concurrent neoadjuvant therapies&#xD;
&#xD;
          -  No other concurrent flaxseed consumption&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy Demark-Wahnefried, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Demark-Wahnefried W, Robertson CN, Walther PJ, Polascik TJ, Paulson DF, Vollmer RT. Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology. 2004 May;63(5):900-4.</citation>
    <PMID>15134976</PMID>
  </reference>
  <reference>
    <citation>Lin X, Gingrich JR, Bao W, Li J, Haroon ZA, Demark-Wahnefried W. Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice. Urology. 2002 Nov;60(5):919-24.</citation>
    <PMID>12429338</PMID>
  </reference>
  <results_reference>
    <citation>Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MT 4th, Snyder DC, Owzar K, Hars V, Albala DM, Walther PJ, Robertson CN, Moul JW, Dunn BK, Brenner D, Minasian L, Stella P, Vollmer RT. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3577-87. doi: 10.1158/1055-9965.EPI-08-0008.</citation>
    <PMID>19064574</PMID>
  </results_reference>
  <results_reference>
    <citation>Demark-Wahnefried W, George SL, Switzer BR, Snyder DC, Madden JF, Polascik TJ, Ruffin MT 4th, Vollmer RT. Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer. Clin Trials. 2008;5(3):262-72. doi: 10.1177/1740774508091676.</citation>
    <PMID>18559416</PMID>
  </results_reference>
  <results_reference>
    <citation>Heymach JV, Shackleford TJ, Tran HT, Yoo SY, Do KA, Wergin M, Saintigny P, Vollmer RT, Polascik TJ, Snyder DC, Ruffin MT 4th, Yan S, Dewhirst M, Kunnumakkara AB, Aggarwal BB, Demark-Wahnefried W. Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila). 2011 Oct;4(10):1590-8. doi: 10.1158/1940-6207.CAPR-10-0136. Epub 2011 Jul 15.</citation>
    <PMID>21764858</PMID>
  </results_reference>
  <results_reference>
    <citation>Azrad M, Zhang K, Vollmer RT, Madden J, Polascik TJ, Snyder DC, Ruffin MT, Moul JW, Brenner D, Hardy RW, Demark-Wahnefried W. Prostatic alpha-linolenic acid (ALA) is positively associated with aggressive prostate cancer: a relationship which may depend on genetic variation in ALA metabolism. PLoS One. 2012;7(12):e53104. doi: 10.1371/journal.pone.0053104. Epub 2012 Dec 28.</citation>
    <PMID>23285256</PMID>
  </results_reference>
  <results_reference>
    <citation>Azrad M, Vollmer RT, Madden J, Dewhirst M, Polascik TJ, Snyder DC, Ruffin MT, Moul JW, Brenner DE, Demark-Wahnefried W. Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer. J Med Food. 2013 Apr;16(4):357-60. doi: 10.1089/jmf.2012.0159.</citation>
    <PMID>23566060</PMID>
  </results_reference>
  <results_reference>
    <citation>Azrad M, Vollmer RT, Madden J, Polascik TJ, Snyder DC, Ruffin MT 4th, Moul JW, Brenner D, He X, Demark-Wahnefried W. Disparate results between proliferation rates of surgically excised prostate tumors and an in vitro bioassay using sera from a positive randomized controlled trial. Biotech Histochem. 2015 Apr;90(3):184-9. doi: 10.3109/10520295.2014.976840. Epub 2014 Dec 1.</citation>
    <PMID>25434394</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>November 12, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

